TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm” or the “Company”), a leading global medical provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions, announces the execution of an ECG and multiple biosign monitoring device integration and co-marketing agreement with California-based BodiMetrics LLC (“BodiMetrics”).
With the launch of CardioComm’s GEMS™ Universal ECG app (“GEMS™ Universal”), BodiMetrics users can now benefit from access to CardioComm’s trusted ECG report generation and reporting capabilities. BodiMetrics will promote the use of GEMS™ Universal to its extensive customer base and CardioComm will share resultant revenues generated from GEMS™ Universal subscription fees and from paid-for ECG readings. Under the agreement, CardioComm also has distribution rights for the sale of devices through its hospital, telemedicine and consumer sales channels.
GEMS™ Universal will be available under two subscription models:
- $6 US per month with one free ECG interpretation included; and,
- $69 US per year with 12 free ECG interpretations that may be requested any time during the one year subscription.
GEMS™ Universal is based directly on the Company’s GEMS™ Mobile ECG and was developed to allow non-HeartCheck™ branded ECG devices users to generate unlimited, medical-grade ECG PDFs or to request a review of their ECG(s) through CardioComm’s SMART Monitoring ECG reading service on a fee-for-review basis. Once the free ECG reviews have been used, additional SMART Monitoring reviews can be requested for $1.99 US for an ECG triage or $12.50 US for a physician interpretation.
The BodiMetrics device replaces five (5) devices with one: ECG, Heart Rate, Systolic Blood Pressure, Blood Oxygenation (Spo2%) and Temperature. BodiMetrics confirms that approximately 30,000 devices have been sold to date with annual sales volumes increasing 50% to 60% each year. US sales occur through Amazon, Best Buy, Costco and various e-commerce channels. Additional sales occur through medical device distributors, Medline, Henry Schein, employer care management partners and telemedicine, patient and virtual care platforms.
A second phase of the agreement will see the GEMS™ Mobile’s ECG management technology embedded directly into BodiMetrics’ device app under a licensing agreement, allowing the user to open only one app to access all existing biometric use options as well as ECG monitoring. Additional information will be provided when the ECG enabled BodiMetrics app is released later this year.
The Company reported the launch of the GEMS™ Universal ECG app on May 14, 2019. The app is now available on Google Play and is scheduled to be available on the App Store within two weeks.
For further updates regarding GEMS™ Mobile ECG device partnerships please see the Companies websites at
www.cardiocommsolutions.com and www.theheartcheck.com.
